Tag: MPO inhibitor
-
Two Gates in Heart Failure: A Drug That Bound Its Target and Still Failed, and One That Passed Its Trial and Still Split on Reimbursement
Evidence-first notes on bioscience and deep tech, at the edge of the lab and the market. Information only — not investment advice, and not medical advice. This piece covers two separate, publicly documented events in the same disease area: a completed, peer-reviewed phase 2b trial (not a simulation, not a preprint) and two national health-technology-assessment…
Uthando Nethemba 